Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 391

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 391
---
MENTS

On December 31, 2024, we had outstanding obligations for future purchase commitments, which become due asfollows:

                            Total                   Less than                                             1 - 3              
                                                    1 year                                                years              
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                (Euro, in thousands)                         
  Purchase commitments      €          272,240      €              189,662                                           70,323  

On December 31, 2023, we had outstanding obligations for future purchase commitments, which become due asfollows:

                            Total                   Less than                                             1 - 3               
                                                    1 year                                                years               
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                (Euro, in thousands)                          
  Purchase commitments      €          408,521      €              237,495                                €          143,532  

Our purchase commitments at the end of the year 2024 included €160.9million related to projects in development phase (2023: €239.6million), €60.9million for projects in discovery research phase (2023: €79.0million), €46.0million for shared services (2023: €45.9million), €1.7million for commercial and medical affairs (2023: €29.9 million), and €2.6million related to Jyseleca® product supply chain (2023: €14.2million).

At year end 2024, our purchase commitments towards NovAliX amounted to €41.6million and were included in the €60.9million related to discovery research. We refer to note 29 for more information about the transaction with NovAliX.

On January 31, 2024, we completed the transaction of the transfer of the Jyseleca® business to Alfasigma. In accordance with common practice, we gave customary representations and warranties which are capped and limited in time. We have an obligation towards Alfasigma to bear certain well-defined post completion costs incurred at their end that go beyond a predetermined level. No provision for such liability was made at December 31, 2024.

On May 30, 2024, we entered into a collaboration and Exclusive License agreement with Adaptimmune. Under the terms of this agreement, we have the obligation to pay potential R& D funding amounting to $15.0million, option exercise fees of